Clusterin Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma

Wojciech Mydlarz1, Mamoru Uemura1, Sun Ahn1, Patrick Hennessey1, Steven Chang1, Semra Demokan4, Wen Yue Sun1, Chunbo Shao1, Justin Bishop2, Julie Kroesting5, Elizabeth Mambo5, William Westra2, Patrick Ha1,3, David Sidransky1, and Joseph Califano1,3

Abstract

Purpose: MicroRNA-21 (miRNA-21) has proto-oncogenic properties, although no miRNA-21–specific targets have been found in head and neck squamous cell carcinoma (HNSCC). Further study of miRNA-21 and its specific targets is essential to understanding HNSCC biology.

Experimental Design: miRNA expression profiles of 10 HNSCCs and 10 normal mucosa samples were investigated using a custom miRNA microarray. Thirteen HNSCCs and five normal mucosa primary tissue specimens underwent mRNA expression microarray analysis. To identify miRNA-21 downstream targets, oral keratinocyte cells were subjected to microarray analysis after miRNA-21 transient transfection. miRNA and mRNA expression were validated by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in a separate cohort of 16 HNSCCs and 15 normal mucosal samples. Microarray and bioinformatics analyses were integrated to identify potential gene targets. In vitro assays looked at the function and interaction of miRNA-21 and its specific gene targets.

Results: miRNA-21 was upregulated in HNSCCs and stimulated cell growth. Integrated analyses identified Clusterin (CLU) as a potential miRNA-21 gene target. CLU was downregulated after forced expression of miRNA-21 in normal and HNSCC cell lines. The activity of a luciferase construct containing the 3′-untranslated region (UTR) of CLU was repressed by the ectopic expression of miRNA-21. CLU was also downregulated in primary HNSCCs and correlated with miRNA-21 overexpression. CLU variant 1 (CLU-1) was the predominant splice variant in HNSCCs and showed growth suppression function that was reversed by miRNA-21 overexpression.

Conclusions: CLU is a specific, functional target of oncogenic miRNA-21 in HNSCCs. CLU-1 isoform is the predominant growth-suppressive variant targeted by miRNA-21. Clin Cancer Res 1–10. ©2013 AACR.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. More than 48,000 new cases of HNSCCs are diagnosed in the United States annually. The 5-year overall survival rate remains around 50% partly due to advanced disease stage at diagnosis and the relatively high local and regional recurrence rates (1, 2). The development of reliable biomarkers and more effective therapeutic agents are necessary to improve patient outcomes.

A major advance in cancer biology in the last decade is the discovery of small regulatory noncoding RNAs including microRNA (miRNA). A single miRNA may regulate the expression of many genes, and it has been proposed that more than one third of all protein-coding genes are under translational control by miRNA (3). These specific gene targets of miRNA are thought to be involved in cellular processes including differentiation, apoptosis, and proliferation and seem to play an important role in a variety of human diseases including cancer (4). Expression profiles of miRNA can be established and seem to be unique for various types of cancers (5).

In this study, we verify that miRNA-21 is overexpressed in HNSCCs and has proto-oncogenic properties through the regulation of Clusterin (CLU). Although no miRNA-21–specific targets have been found in HNSCCs to date, several recent reports identified miRNA-21 alterations in primary HNSCC tissue samples (6–9). CLU only recently has been associated with cancer promotion and metastasis (10–12). CLU is considered as an enigmatic molecule because of the difficulties in the definition of its precise function. The role

Authors' Affiliations: Departments of 1Otolaryngology-Head and Neck Surgery and 2Pathology, Johns Hopkins Medical Institutions; 3The Milton J Dance, Jr. Head and Neck Center, Greater Baltimore Medical Center, Baltimore, Maryland; 4Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey; and 5Asuragen, Inc. Austin, Texas

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

W. Mydlarz and M. Uemura equally contributed to this work.

Corresponding Author: Joseph Califano, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, 1550 E Orleans Street, GRB II, Room 504, Baltimore, MD 21231. Phone: 410-502-2692; Fax: 410-502-2693; E-mail: jcalifa@jhmi.edu
doi: 10.1158/1078-0432.CCR-13-2675
©2013 American Association for Cancer Research.

www.aacrjournals.org

Published OnlineFirst December 10, 2013; DOI: 10.1158/1078-0432.CCR-13-2675

Downloaded from clincancerres.aacrjournals.org on April 8, 2017. © 2013 American Association for Cancer Research.
of CLU in carcinogenesis is unclear, with evidence that CLU has either a proapoptotic or a prosurvival role (11, 13–15). It is now clear that CLU encodes at least 2 major mRNA variants, but still very little is known about their biologic relevance and regulation (16). Expression pattern of CLU and its transcript variants is unknown in HNSCCs and normal tissues. The aims of this study were: (i) to profile the miRNA expression in HNSCC, (ii) to identify miRNA-21 targets that play a crucial role in HNSCCs using an integrative microarray and bioinformatics techniques, and (iii) to reveal the function of CLU and its regulation in HNSCCs by a variant-specific approach.

Materials and Methods

Human tissue samples

All human HNSCC tissue samples and normal mucosal tissues were obtained and used according to the policies of the JHMI institutional review board. Surgical specimens were obtained from surgical patients at John Hopkins Hospital. All specimens were quick-frozen in liquid nitrogen and stored at −80°C. Microdissection of frozen tumor tissue was conducted by a head and neck pathologist to assure HNSCC tumor yield of greater than 80%.

Ten normal and 10 HNSCC tissues were obtained for the microRNA microarray analysis. Normal tissues were obtained from patients that underwent uvulopalatopharyngoplasty (UPPP) for sleep apnea, and the cancer tissues consisted of 9 stage IV and 1 stage III HNSCC (Supplementary Table S1). A separate cohort of primary tissue including 13 HNSCC and 5 normal mucosa UPPP specimens underwent mRNA expression microarray analysis. The tumors consisted of 7 oropharynx, 6 oral cavity, 2 larynx, and a hypopharynx cancers (Supplementary Table S2). For miRNA-21 and CLU expression qRT-PCR validation study, another separate cohort of 16 HNSCC tumors and 15 normal mucosal UPPP tissues was used (Supplementary Table S3).

Cell lines and culturing conditions

Normal oral keratinocyte. Spontaneously immortalized cell line (NOK-SI) was developed by National Institute of Dental and Craniofacial Research collaborators at the NIH as previously described (17). NOKSI cells were grown in keratinocyte serum-free medium supplemented with bovine pituitary extract, EGF, and 1% penicillin/streptomycin. The HNSCC cell lines FaDu and SCC9 were expanded and passaged in DMEM/F12 medium supplemented with 10% FBS, 1% penicillin/streptomycin, and hydrocortisone (0.4 µg/mL). JHU-O28 HNSCC cell line was expanded and passaged in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. All media components were obtained from Gibco Invitrogen Corporation. Cell growth conditions were maintained at 37°C in an atmosphere of 5% carbon dioxide and 95% relative humidity.

Transfection of miRNA-21, CLU transcript variant 1, and luciferase constructs

The miRNA-21 overexpression vector pMIF-cGFP-Zeo-hsa-pre-miRNA-21 (MIFCZ307PA-1) and pMIF-c-GFP-Zeo (MIFCZ300PA-1) empty vector control were purchased from System Biosciences. CLU variant 1 (CLU-1) expression vector (Origene) was used to confirm the function of CLU-1.

Luciferase constructs containing the 3′-untranslated region (UTR) of CLU and control luciferase vectors (GeneCopeia) were used to conduct luciferase reporter assays. The miRNA-21–binding seed sequence was removed from the CLU 3′-UTR region by cutting out a 120-bp segment using double restriction enzyme digestion and reannealing the CLU luciferase vector per standard protocol and conditions. DNA sequencing was conducted to verify deletion of the miRNA-21 seed sequence from the CLU 3′-UTR sequence within the CLU luciferase vector. Transient transfections were conducted in NOK-SI cells using FuGENE6 reagent (Roche Applied Science) according to the manufacturer’s protocols. Each experiment was carried out independently in triplicate and at least 3 times.

Cell proliferation assay

NOK-SI, FaDu, JHU-O28, and SCC9 cells were plated at a confluence of 20% per well of a 96-well plate. Growth was assayed at 24, 48, and 72 hours by Cell Counting Kit-8 (CCK-8) cell proliferation assay (Dojindo Molecular Technologies, Inc.). The standard manufacturer protocol was followed. All experimental conditions were carried out in sextuplicate. Average fluorescence absorbance readings were taken with SpectraMax M2e Microplate reader (Molecular Devices) at 450 and 650 nm wavelengths. Confirmatory cell proliferation studies were conducted in 6-well plates in triplicate. Gross cell number at each time point was measured via direct cell counting using a hemacytometer (Fisher Scientific). The average of 3 cell counts per well was reported.

miRNA and RNA isolation, quantification, and cDNA formation

Total RNA from primary human tissue and cell lines was extracted using TRIzol reagent (Invitrogen). For miRNA
array experiments, total RNA was extracted using the mirVana miRNA Isolation Kit (Ambion/Applied Biosystems). Reverse transcription of RNA was conducted using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). For miRNA-specific cDNA formation, each sample was subjected to a reverse transcription reaction as part of the TaqMan MicroRNA Assay Kit (Applied Biosystems). All RNA samples were stored at −80°C whereas cDNA samples at −20°C. All experiments were carried out according to manufacturer’s protocols.

miRNA array

Northern blots were conducted to assure that the quality of RNA was adequate. RNA integrity was evaluated using denaturing gels and detection of the 18S and 28S rRNA bands. This assured that the RNA lacked DNA contamination and that the RNA was not degraded, both of which could confound the array results. A custom-manufactured Affymetrix GeneChip from Asuragen (DiscovArray) was designed to miRNA probes derived from Sanger mirBase v9.2 database and published reports (18, 19). Antigenomic probe sequences were provided by Affymetrix and derived from a larger set of controls used on the Affymetrix human exon array for estimating background signal, as described below. Other non-miRNA control probes were designed to have no sequence homology to the human genome and were used for spike-in external reference controls. The 3′ ends of the RNA molecules were labeled with biotin using the mirVana miRNA Labeling Kit (Life Technology). The Kit’s dNTP mixture in the tailing reaction was replaced with a nucleotide mixture containing biotin-modified nucleotides (PerkinElmer). Labeled RNA was profiled by hybridization to the above-described custom microchip. Hybridization, washing, staining, imaging, and signal extraction were conducted according to Affymetrix protocols. Briefly, 100 ng of total RNA was labeled and hybridized to the microarray with about 13,000 probes including 600 known miRNA as well as putative miRNAs.

miRNA array data analysis

The signal processing implemented for the custom miRNA chip (DiscovArray) is a multistep process involving probe-specific signal detection calls, background estimate and correction, constant variance stabilization (20), and either array scaling or global normalization. For each probe, an estimated background value was subtracted that is derived from the median signal of a set of GC content-matched anti-genomic controls. Arrays within a specific analysis experiment were normalized together according to the variance stabilization normalization (VSN) method described by Huber and colleagues. Detection calls were based on a Wilcoxon rank-sum test of the miRNA probe signal compared with the distribution of signals from GC content-matched anti-genomic probes. Comparison between tumor and normal was tested with a 2-sample t test with assumption of equal variance. One-way ANOVA was used for experimental designs with more than 2 experimental groupings (normal vs. tumor). These tests defined which probes were considered to be significantly differentially expressed, or “significant”, based on a default P value of less than 0.05 and at least 2-fold change (log2 difference ≥1). Array-based differentially expressed miRNAs were further tested by quantitative PCR (qPCR) as described below.

Validation of miRNA array results by qRT-PCR

cDNA was synthesized from total RNA using gene-specific primers according to the TaqMan MicroRNA Assay protocol (Applied Biosystems). Reverse transcription was conducted in 10 μL reactions containing 15 ng of total RNA isolated from the same human tissue samples used for the miRNA array. Reactions were incubated in a 9700 Applied Biosystems (ABI) ThermaCycler in a 96-well plate for 30 minutes at 16°C, 30 minutes at 42°C, 5 minutes at 85°C. Two microliters of the RT reaction were used in the 15 μL real-time qPCR reaction conducted on an Applied Biosystems 7900 Sequence Detection system using ABI’s TaqMan primer and probes for PCR amplification. The reaction conditions were according to the TaqMan MicroRNA Assay protocol. Each sample was measured in duplicate RT reactions. We used the ΔΔCt values to identify candidate biomarkers for distinguishing HNSCCs from normal tissues using the ΔΔCt method (21).

Validation of miRNA-21 results by RT-qPCR in separate human tissue sample cohort

Extracted total RNA from HNSCC tumor and normal tissue was subjected to miRNA-specific RT-qPCR as per the manufacturer protocol (Applied Biosystems). RT-qPCR for miRNA was carried out as described previously (7). The expression was normalized to U47 expression. The expression level was again determined by the ΔΔCt method (21). The average miRNA-21 expression level in normal versus tumor tissue was determined using the Mann–Whitney U test.

mRNA microarray

Total RNA extraction from HNSCCs and normal mucosal human tissue samples and NOK-SI cells were conducted using TRIzol reagent, as above. RNA was further purified using the RNeasy Kit (Qiagen). Northern blots were conducted to assure that the quality of RNA was adequate. RNA integrity was evaluated on a denaturing gel and evaluating the presence of 18S and 28S rRNA. mRNA microarray analysis was conducted using the Affymetrix U133 Plus 2.0 array platform, both for the primary tissue and the NOK-SI cell line experiments samples. Significance analysis of microarrays (SAM) was conducted to determine differential mRNA expression. A q-value or FDR was set at 5% to determine significant genes.

Quantification of CLU expression by RT-qPCR

Applied Biosystems gene expression kit Hs00971651_m1 specific for CLU was used for qPCR studies. The expression was normalized to 18s expression, using the Applied Biosystems gene expression kit Hs99999901_s1. The expression
level was again determined by the ΔΔCt method (21). The CLU expression level in normal versus tumor tissue was determined using the Mann–Whitney U test.

**Absolute quantification of CLU differential transcript expression by RT-qPCR**

To further elucidate the baseline specific expression pattern of CLU in NOK-SI cell line, CLU transcript variant 1 (CLU-1) and CLU transcript variant 2 (CLU-2) specific primers were used to quantify the absolute expression ratio of each variant. Variant-specific primer sequences were as follows (22): CLU-1, 5′-ACAGGGTGCGGCTGAC-3′ (forward) and 5′-CCAGGACCTGCCCACCTCT-3′ (reverse); CLU-2, 5′-ATGCAGATGATTCGCTG-3′ (forward) and 5′-AGTCCTTTGGACCGCTCTGA-3′ (reverse). Purified PCR products were synthesized using CLU-1- and CLU-2-specific primers. Using standard curves based on the diluted purified PCR products, the input copy number of each transcript was determined by SYBR Green (Applied Biosystems) qRT-PCR.

**Luciferase reporter assay**

At 48 hours after transfection of miRNA-21 and the luciferase plasmids into NOK-SI cells, luciferase assays were conducted using the Dual-Luciferase Reporter Assay System (Promega) as per the manufacturer’s instructions. Luminescent signal was quantified by the luminometer (Monolight 3020; BD Biosciences). Each Renilla luciferase value was first normalized to the control firefly luciferase assay value contained in each luciferase construct. Each value is a mean of 3 separate transfections measured in triplicate.

**Results**

**Identification of upregulated miRNAs in HNSCCs**

miRNA expression profiles of HNSCCs were investigated using a miRNA microarray platform. Profiles from tumor samples (n = 10) and non-tumor tissues (n = 10) were compared (Supplementary Table S4). Thirty-two differentially expressed miRNAs were identified by miRNA array (Supplementary Table S5). To validate the microarray data, expression profiles of these miRNAs were analyzed by RT-qPCR in the same cohort of clinical samples that was used in miRNA array. Twenty-one significantly upregulated miRNAs were identified (Supplementary Table S6), miRNA-21, miRNA-155, and miRNA-375 have been previously reported as differentially expressed in HNSCCs, but no specific gene targets of these miRNAs have been reported as of yet in HNSCC tumors (7, 8).

Among this group, miRNA-21 was one of the most notably upregulated in tumor tissues (P = 0.0002). miRNA-21 plays a potential important role in carcinogenesis as there are increasing number of reports showing aberrant expression of this miRNA in many different tumor types. miRNA-21 has been implicated in tumor growth, carcinogenesis, and response to chemotherapy in different malignancies (7, 23–29). Given its potential active role across many different tumor types, including HNSCCs, miRNA-21 was selected as the miRNA of choice for target identification experiments. For further validation, miRNA-21 expression was examined in a separate validation cohort of 16 HNSCC tumors and 15 normal mucosal tissues. Upregulation of miRNA-21 in tumors was again confirmed (Supplementary Fig. S1, P = 0.0007).

**Impact of miRNA-21 on cell growth**

To confirm the well-known fact that miRNA-21 is an oncogenic miRNA (23, 30, 31), impact of miRNA-21 cell growth was examined. The miRNA-21 overexpression vector pMIF-cGFP-Zeo-hsa-pre-miRNA-21and empty control vector pMIF-cGFP-Zeo were transfected in the NOK-SI cell line. Overexpression of miRNA-21 was confirmed by qRT-PCR. The overexpression vector produced over a 5,000-fold increase in pre-miRNA-21 and almost a 4-fold increase in miRNA-21 expression when compared with the control vector (Supplementary Fig. S2). In NOKSI, overexpression of miRNA-21 significantly stimulated proliferation compared with the negative empty vector control. At the 72-hour time point after transfection, the miRNA-21–overexpressed cells exhibited a 40.4% (P = 0.0022) increase in cell growth compared with the empty vector (Supplementary Fig. S3).

**Identification of miRNA-21–specific target**

Bioinformatics tools (TargetScan, PicTar, miRanda) were used to predict the potential miRNA-21 gene targets. Results revealed that miRNA-21 has more than 1,200 potential gene targets (Supplementary Tables S7–S9). This presented a logistical challenge to find a way to narrow this extensive list and identify gene-specific targets of miRNA-21. The ultimate research strategy included in silico bioinformatics tools, as well as in vitro cell line and in vivo primary tissue studies (Fig. 1). In vitro experiments using the normal oral keratinocyte (NOK-SI) cell line were used to overexpress miRNA-21 as described earlier. To capture and identify the potential expression changes that occur due to miRNA-21 overexpression and its downstream target genes, NOK-SI cells were subjected to miRNA microarray analysis after 72-hour transient transfection with miRNA-21 overexpression vector or its negative control. Affymetrix U133 Plus 2.0 array platform was used and 97 upregulated and 60 downregulated genes were identified (Supplementary Table S10).

In vivo studies included evaluation of the mRNA expression differences between normal mucosal and HNSCC tumor tissues. The Affymetrix U133 Plus 2.0 array platform was again used to evaluate differential mRNA expression in an independent tissue bank cohort that was separate from the primary tissue used in the miRNA discovery array. Analysis of the differential expression data revealed statistical significance in 368 upregulated and 6,912 downregulated genes (Supplementary Table S11).

Results from all 3 arms of the experimental design were then combined in a novel integrative approach to narrow down possible miRNA-21 gene targets in HNSCCs. The 60 differentially downregulated miRNAs identified on the microarray analysis of in vitro miRNA-21–overexpressed NOK-SI cell line samples were only accepted as potential...
miRNA-21 targets if they could be verified by the in silico bioinformatics tools for gene target prediction. This preliminary list was then compared with the in vivo array results of downregulated mRNAs generated by comparing differential mRNA expression of HNSCCs and normal mucosal tissues. An integrative approach was used to formulate a product rank order list based on potential miRNA-21 gene targets identified so far by combining the in vitro and in silico approaches and comparing them with downregulated mRNAs identified in the in vivo experimental arm (Fig. 1).

Combining these 3 approaches generated a candidate gene list (Table 1). Clusterin (CLU) was the most statistically significant downregulated gene target identified during this integrative analysis, and CLU mRNA was downregulated by the forced expression of miRNA-21 in NOKSI cell line (Fig. 2A).

miRNA-21 targets the 3'-UTR of CLU

In order for CLU to be a specific gene target of miRNA-21 and undergo expression repression by this miRNA, the 3'-UTR of the mRNA transcript should contain miRNA-21–specific binding sites. miRNA-21 must recognize these sites and directly bind to this 3'-UTR of the mRNA transcript. To

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Official symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clusterin</td>
<td>CLU</td>
</tr>
<tr>
<td>Basonuclin 2</td>
<td>BNC2</td>
</tr>
<tr>
<td>Desmin</td>
<td>FAM48a</td>
</tr>
<tr>
<td>Protein phosphatase 1, regulatory subunit 3E</td>
<td>PPP1R3E</td>
</tr>
<tr>
<td>Estrogen receptor 2</td>
<td>ESR2</td>
</tr>
<tr>
<td>Tumor necrosis factor 2</td>
<td>TNF2</td>
</tr>
<tr>
<td>Fibroblast growth factor 5</td>
<td>FGF5</td>
</tr>
<tr>
<td>B-cell CLL/lymphoma 2</td>
<td>BCL2</td>
</tr>
<tr>
<td>Programmed cell death 4</td>
<td>PDCD4</td>
</tr>
<tr>
<td>Pleiomorphic adenoma gene 1</td>
<td>PLAG1</td>
</tr>
</tbody>
</table>

Figure 1. Study flowchart.

| Table 1. Potential targets of miRNA-21 |

www.aacrjournals.org  Clin Cancer Res; 2014  OF5

Published OnlineFirst December 10, 2013; DOI: 10.1158/1078-0432.CCR-13-2675

Downloaded from clincancerres.aacrjournals.org on April 8, 2017. © 2013 American Association for Cancer Research.
demonstrate this, the 3′-UTR of CLU that contained all the predicted miRNA-21–binding sites was cloned into a luciferase reporter construct. Cotransfection of miRNA-21 overexpression vector along with the CLU 3′-UTR sequence containing a luciferase reporter construct was conducted to show specific binding and recognition of miRNA-21 for the CLU 3′-UTR. Activity of a luciferase reporter containing the predicted microRNA-binding sequences of CLU 3′-UTR was repressed by the ectopic expression of miRNA-21 (Fig. 2B). miRNA-21 specificity for the CLU 3′-UTR was lost when a short segment containing the miRNA-21 seed sequence was deleted from within the CLU 3′-UTR region of the same luciferase reporter construct (Supplementary Fig. S4).

### Variant-specific analysis of CLU expression

There are 2 main variants in CLU (16), and both of them have a common 3′-UTR sequence. Experimental evidence shows that these 2 different CLU transcript variants may have varying proapoptotic or prosurvival functions. Expression pattern of CLU and its transcript variants as well as the specific function of CLU is unknown in HNSCCs and normal tissues to date. Therefore, it was important to evaluate the variant-specific expression pattern of the 2 major CLU mRNA transcript variants. Absolute quantification of CLU-1/CLU-2 was conducted in NOKSI cell line and 16 HNSCC tumor samples (Supplementary Table S3). In both NOKSI and HNSCC tumors, CLU-1 was by far the dominant variant by RT-qPCR (copy numbers of CLU-1 and CLU-2 were 7,717 ± 2,684 and 106 ± 87, respectively; P < 0.0001; Fig. 3). CLU-1 expression was also verified in NOKSI and other HNSCC cell lines, with NOKSI showing the highest expression of CLU-1 (Supplementary Fig. S5).

### Impact of CLU-1 on cell growth

The goal of this study was to identify key biologically active gene targets of miRNA-21 in HNSCCs. miRNA-21 is overexpressed in HNSCC primary tissue and has proto-oncogenic activity in vitro (7). Biologically significant targets should therefore in the least induce growth suppression when actively expressed. Growth effects of CLU-1 were then evaluated in vitro. CLU-1 was transiently overexpressed in NOKSI cell line to help clarify its potential effects on cell...
proliferation and results obtained using absorbance readings at regular 24-hour time point increments (Fig. 4). Overexpression of CLU-1 was confirmed by RT-qPCR (Supplementary Fig. 6).

In NOKSI, overexpression of CLU-1 inhibited proliferation compared with negative control. At the 72-hour time point after transfection, the CLU-1–overexpressed cells exhibited a 19.6% \( (P = 0.0022) \) reduction in cell growth compared with the empty vector transfected cells (Fig. 4A). Similar growth-inhibitory results were obtained in HNSCC cell lines when CLU-1 was overexpressed in JHU-O28, FaDu, and SCC9. Cell counts at various time points were obtained by direct real-time cell counting as described previously (Supplementary Fig. 7).

All of the experimental analyses in this study clearly show that miRNA-21 specifically recognizes and downregulates a specific isoform of CLU, CLU-1, in head and neck mucosal tissue. miRNA-21 overexpression represses the growth-inhibitory CLU-1 by specifically binding to the 3’-UTR and effectively stimulates growth proliferation in cells.

To further validate miRNA-21 specificity and regulation of CLU-1, overexpression of CLU-1 and the resulting growth suppression should be inhibited if not reversed by miRNA-21 overexpression. To confirm the regulation of CLU by miRNA-21, cotransfection was conducted using miRNA-21 expression vector and CLU-1 expression vector in the NOKSI cell line. Cell growth inhibitory effect of CLU-1 was reversed by cotransfection of miRNA-21 expression vector.
as measured with the CCK-8 cell growth kit (Fig. 4B). These results were repeated and verified by quantifying cell growth with direct cell number counts at each time point (data not published).

**Relation between the expression of miRNA-21 and CLU in HNSCC**

Given the specificity of miRNA-21 for CLU and the CLU-1 transcript variant, expression of both genes was analyzed in primary tissue samples. If CLU and CLU-1 play an important potential role in HNSCC carcinogenesis, miRNA-21 expression in tumors should correlate with repression of CLU. Analysis was conducted in a separate cohort of 16 HNSCC tumors and 15 normal UPP mucosal samples (Supplementary Table S3). CLU was significantly downregulated in primary HNSCCs compared with normal mucosa tissue ($P = 0.0006$, Fig. 5A). On the other hand, as shown in Supplementary Fig. S1, miRNA-21 expression was significantly upregulated in tumor ($P = 0.0007$). There was a significant inverse correlation between miRNA-21 expression and CLU expression. The Spearman correlation coefficient between miRNA-21 and CLU was $-0.449$ ($P = 0.0114$, Fig. 5B).

**Discussion**

A large-scale survey to determine the miRNA signature of 540 tumor samples including lung, breast, stomach, prostate, colon, and pancreatic tumors revealed that miRNA-21 was the only miRNA upregulated in all these tumors (32). Recently, emerging evidence indicates that miRNA-21 has oncogenic properties (23, 30, 31), and inhibition of miRNA-21 could provide a new therapeutic strategy in cancer through the Ras/MEK/ERK pathway and apoptosis (33). However, regarding HNSCC, little is known about the role of miRNA-21 and all of its potential targets.

Each miRNA targets numerous genes simultaneously (34, 35), so it is quite difficult to identify targets of miRNAs that have crucial role in regulation of cancer biology. In this study, we have successfully narrowed down the candidates of specific target of miRNA-21 by the combination of microarray analysis and bioinformatics target prediction tools. Our results indicated that miRNA-21 expression modulates cell growth via regulation of CLU and more specifically CLU-1, a CLU mRNA transcript variant with growth-suppressive function. Furthermore, in clinical tissue samples, significant inverse correlation between miRNA-21 expression and CLU expression was observed. It is usually difficult to determine the significant correlation between miRNAs expression and their predicted targets in clinical samples (27, 36). So these results suggest that CLU is an important target of oncogenic miRNA-21 in HNSCCs, and miRNA-21 might be a key regulator of CLU in HNSCCs.

The accumulated evidence indicates that CLU has many biologic functions and plays an important role in cancer biology (37, 38). Now it is generally accepted that there are 2 alternative isoforms of CLU protein; the secreted CLU (sCLU) and the nuclear form of CLU (nCLU). The existence of sCLU and nCLU might explain the contradictory role of CLU. sCLU is usually reported as a survival factor; on the other hand, nCLU is considered as proapoptotic associated with cell death (13, 39–42). During the last decade, many studies have discussed the complexity of CLU, but there is still a lack of precise information about the complex regulation of its expression, so CLU has been defined as an enigmatic protein.

Several reports have indicated that CLU-1 may account for the existence of the nuclear form of CLU (nCLU; refs. 16, 43) and CLU-2 encodes for a secreted CLU (sCLU; refs. 16, 44, 45).

We identified CLU-1 as the dominant variant expressed in HNSCCs that is regulated by miRNA-21. Our results also suggest that nCLU might originate at least partially from CLU-1 because forced expression of CLU-1 resulted in growth inhibition. It is now clear that CLU encodes more than one mRNA, but it still remains unclear how the protein isoforms are produced from the CLU gene and how each transcript relates to the diverse CLU isoforms (46). Furthermore, it is important to note that none of studies have isolated and sequenced the intracellular CLU (46), so it is difficult to make a definitive conclusion about the origin of nCLU.

Several oncogenes including H-Ras, cMyc, and N-Myc generally downregulate CLU (47–49), so it is hypothesized that suppression of CLU by oncogenes is required for oncogene-dependent transformation (46). Our finding supports this hypothesis because miRNA-21 is an oncogenic microRNA. It is still hard to reveal the complexity of CLU regulation, but variant-specific analysis of CLU at the transcriptional level may provide clues to understanding the complexity of CLU. However, further studies are necessary to reveal the mechanism for tissue-specific regulation of CLU.

Novel miRNA targets can be identified and validated using a combined microarray analysis and bioinformatics target prediction methods. miRNA-21 is one of the crucial regulators for CLU, so there is a significant inverse correlation between miRNA-21 and CLU in clinical tissue samples. Further study is necessary to evaluate the potential diagnostic and prognostic significance and even possibly therapeutic importance of CLU in HNSCCs.

**Disclosure of Potential Conflicts of Interest**

The researchers at Asuragen, Inc. who participated in this study were not influenced by management or parties outside of their research group and had exclusive control over study design, data collection, analysis, decision to publish, and preparation of the manuscript. No potential conflicts of interest were disclosed.

**Authors’ Contributions**

Conception and design: W. Mydlarz, D. Sidransky, J. Califano Development of methodology: W. Mydlarz, E. Mambo, J. Califano Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W. Mydlarz, M. Uemura, S. Ahn, P. Hennessey, W. Sun, C. Shao, J. Bishop, J. Krofting, E. Mambo, W. Westra, P. Ha, J. Califano Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. Mydlarz, M. Uemura, S. Demokan, C. Shao, D. Sidransky, J. Califano
Clusterin Is a microRNA-21 Target in Head and Neck Cancer

Writing, review, and/or revision of the manuscript: W. Myldrazl, M. Umemura, S. Ahn, P. Hennessey, S. Chang, S. Demokan, C. Shao, E. Mambo, P. Ha, J. Califano
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Myldrazl, S. Demokan, J. Bishop, W. Westra, J. Califano
Study supervision: W. Myldrazl, E. Mambo, J. Califano

Grant Support
J. Califano and D. Sidransky are supported by a NCI/NIDCR SPOR (5SPOCA096784-03) and J. Califano is supported by NIDCR Challenge Grant (RC1DE020324). W. Myldrazl and P. Hennessey are funded by the NIH T32 Research Training Grant (T32DC000207). Funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. Study was also funded by Ausragen, Inc. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 28, 2013; accepted December 3, 2013; published OnlineFirst December 10, 2013.

References

www.aacrjournals.org
Clin Cancer Res; 2014 OF9

Downloaded from clinincancerres.aacrjournals.org on April 8, 2017. © 2013 American Association for Cancer Research.


Clusterin Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma

Wojciech Mydlarz, Mamoru Uemura, Sun Ahn, et al.

Clin Cancer Res  Published OnlineFirst December 10, 2013.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-2675

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/12/11/1078-0432.CCR-13-2675.DC1
http://clincancerres.aacrjournals.org/content/suppl/2013/12/11/1078-0432.CCR-13-2675.DC2

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.